Diabetic Nephropathy Market: The SGLT2 Inhibitor Revolution Is Reshaping Kidney Disease Treatment Diabetic kidney disease is one of the most serious and costly complications of diabetes — and one of the most common causes of end-stage renal disease globally. The Diabetic Nephropathy Market, growing from USD 6.79 billion in 2024 to USD 12.89 billion by 2032 at a CAGR of 8.34%, is expanding because the disease burden is large and rising — and because the therapeutic landscape has...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
